Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07146646 · ClinicalTrials.gov registry record · Phase 2

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

A Phase 2 study of Cholangiocarcinoma and Biliary Tract Cancer, sponsored by Case Comprehensive Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
27
Enrollment target
2
Study locations

NCT07146646 is a Phase 2 study of Cholangiocarcinoma and Biliary Tract Cancer that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 27 participants, below the 385-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07146646, a Phase 2 study of Cholangiocarcinoma and Biliary Tract Cancer, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
27 participants
Enrollment target
2
Study locations

Study Summary

Participants are eligible for this study who were treated for advanced biliary tract cancer (BTC) but the treatment either did not make the cancer better or is no longer working. The treatment for patients whose advanced BTC either did not make the cancer better or is no longer working is a combination of chemotherapy drugs called FOLFOX which consists of fluorouracil and oxaliplatin. Studies have shown that other treatments may work better to treat advanced BTC. In this study, investigators want to see if treating patients with the drug combination of trifluridine/tipiracil (FTD/TPI) and another drug called oxaliplatin works better than FOLFOX for advanced BTC as second-line therapy. FTD/TPI are pills that are taken by mouth, whereas oxaliplatin is given intravenously (by IV).

Conditions Studied

Cholangiocarcinoma Biliary Tract Cancer Gallbladder Cancer Biliary Tract Neoplasms Gallbladder Carcinoma

Interventions

  • DRUG Oxaliplatin
  • DRUG Trifluridine/tipiracil

Study Locations (2)

Ohio

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
  • Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2025-12-01
Est. Completion 2027-04
Phase Phase 2

Sponsor

Case Comprehensive Cancer Center

407 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07146646

The ClinicalTrials.gov registry entry for NCT07146646 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 385-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (93% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Oxaliplatin is the first listed.

NCT07146646 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT07146646 about?

NCT07146646 is a clinical study titled "Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer". Participants are eligible for this study who were treated for advanced biliary tract cancer (BTC) but the treatment either did not make the cancer better or is no longer working. The treatment for patients whose advanced BTC either did not make the cancer better or is no longer working is a combinat...

What is the current status of trial NCT07146646?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2025-12-01. Estimated completion is 2027-04.

What conditions does trial NCT07146646 study?

This clinical trial studies the following conditions: Cholangiocarcinoma, Biliary Tract Cancer, Gallbladder Cancer, Biliary Tract Neoplasms, Gallbladder Carcinoma.

What interventions are being tested in trial NCT07146646?

The interventions under investigation include: Oxaliplatin (DRUG), Trifluridine/tipiracil (DRUG).

Who is sponsoring clinical trial NCT07146646?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07146646 being conducted?

This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cholangiocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cholangiocarcinoma

All registered trials for this condition

Biliary Tract Cancer

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.